Craig H Mallinckrodt
Overview
Explore the profile of Craig H Mallinckrodt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dickson S, Mallinckrodt C, Rogula B, Powell L, Potashman M, Coric V, et al.
Neurol Ther
. 2024 Sep;
13(6):1627-1639.
PMID: 39287752
Introduction: The reliable assessment of treatment outcomes for disease-modifying therapies (DMT) in neurodegenerative disease is challenging. The objective of this paper is to describe a generalized framework for developing composite...
2.
Ratitch B, Lipkovich I, Erickson J, Zhang L, Mallinckrodt C
Pharm Stat
. 2018 Jul;
17(6):685-700.
PMID: 30051580
This article focuses on 2 objectives in the analysis of efficacy in long-term extension studies of chronic diseases: (1) defining and discussing estimands of interest in such studies and (2)...
3.
Blauvelt A, Muram T, See K, Mallinckrodt C, Crowley J, van de Kerkhof P
J Dermatolog Treat
. 2017 Aug;
29(3):220-229.
PMID: 28792259
Background: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17 A. Objective: Examine the efficacy of ixekizumab in clearing psoriasis within different body regions. Methods: Data from 3 placebo-...
4.
Jiang H, Kulkarni P, Wang Y, Mallinckrodt C
Pharm Stat
. 2015 Nov;
15(1):46-53.
PMID: 26610282
In randomized clinical trials with time-to-event outcomes, the hazard ratio is commonly used to quantify the treatment effect relative to a control. The Cox regression model is commonly used to...
5.
Jiang H, Kulkarni P, Mallinckrodt C, Shurzinske L, Molenberghs G, Lipkovich I
Pharm Stat
. 2015 Apr;
14(3):262-71.
PMID: 25866149
The benefits of adjusting for baseline covariates are not as straightforward with repeated binary responses as with continuous response variables. Therefore, in this study, we compared different methods for analyzing...
6.
Lipkovich I, Kadziola Z, Xu L, Sugihara T, Mallinckrodt C
J Biopharm Stat
. 2014 Apr;
24(4):924-43.
PMID: 24697735
We evaluated via a simulation study several strategies for imputing missing ordinal outcomes in a longitudinal clinical trial, contrasting methods that involve truncation of imputed values outside plausible ranges with...
7.
Dunner D, Wohlreich M, Mallinckrodt C, Watkin J, Fava M
Curr Ther Res Clin Exp
. 2014 Mar;
66(6):522-40.
PMID: 24678074
Background: To reduce the risk for treatment-emergent adverse events and increase patient compliance, clinicians frequently prescribe a suboptimal starting dose of antidepressants, with the goal of increasing the dose once...
8.
Ayele B, Lipkovich I, Molenberghs G, Mallinckrodt C
J Biopharm Stat
. 2014 Mar;
24(2):211-28.
PMID: 24605966
It is important to understand the effects of a drug as actually taken (effectiveness) and when taken as directed (efficacy). The primary objective of this investigation was to assess the...
9.
Lipkovich I, Mallinckrodt C, Faries D
Pharm Stat
. 2012 Oct;
11(6):485-93.
PMID: 23060290
Assessing dose response from flexible-dose clinical trials is problematic. The true dose effect may be obscured and even reversed in observed data because dose is related to both previous and...
10.
Mallinckrodt C, Tamura R, Tanaka Y
J Psychiatr Res
. 2011 Apr;
45(9):1202-7.
PMID: 21453932
Recent (2007-2010) empirical and theoretical literature on associations of trial design features with signal detection and placebo response were investigated, along with data and analytic considerations. Trials with greater percentages...